drugset / Trial / NCT01486433

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

NCT01486433

Phase 1 Completed 52 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective is to determine the effect of multiple doses of Epanova® (omega fatty acids) on the pharmacokinetics (PK) of multiple 40 mg doses of simvastatin.

Timeline

Start
2011-11
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Simvastatin Small molecule 40 mg
Subject omefas Unknown 4 g
Background Aspirin Small molecule 81 mg

Indications